Mallinckrodt plc Stock Price, News & Analysis
MNKTQ
OTC
Company Description
Mallinckrodt plc is a global specialty pharmaceutical and medical imaging business, focusing on autoimmune and rare diseases in neurology, rheumatology, nephrology, ophthalmology, and pulmonology, amongst other areas. They develop, manufacture, market, and distribute therapy products and medical imaging agents. They have a portfolio of specialty brands and generics, including contrast media and nuclear imaging agents.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$1.6M
Market Cap
13.4M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Mallinckrodt plc.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the market cap of Mallinckrodt plc (MNKTQ)?
The market cap of Mallinckrodt plc (MNKTQ) is approximately 1.6M.
What does Mallinckrodt plc focus on?
Mallinckrodt plc focuses on autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, ophthalmology, and pulmonology.
What kind of products does Mallinckrodt plc offer?
Mallinckrodt plc offers therapeutic drugs for autoimmune and rare diseases, imaging agents, contrast media, nuclear imaging agents, amongst others.
What is Mallinckrodt plc known for?
Mallinckrodt plc is known for its specialty brands segment, specialty generics segment, and the global medical imaging segment.
What recent achievement was highlighted by Mallinckrodt plc?
Mallinckrodt plc recently shared findings from their health economics outcomes research on Acthar® Gel at the Academy of Managed Care Pharmacy Nexus 2023.
How does Mallinckrodt plc aim to improve patient outcomes?
Mallinckrodt plc aims to provide the medical community with up-to-date research to support the availability, use, and potential of their products to improve outcomes for autoimmune and chronic inflammatory conditions.